Created in 2006 (France), I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome own 2757 sister brands and 17478 competing brands. The I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome brand is owned by SANOFI, a company listed in Paris. The ISIN, the company's International Securities Identification Number, is FR0000120578. The sector of I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome is Drug Manufacturers.

I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome is a brand of SANOFI (SAN) Other brands

Buy SANOFI share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Other brands
SANOFI